(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of -11.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 288.79%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.75%.
Alumis's revenue in 2025 is $20,055,000.On average, 10 Wall Street analysts forecast ALMS's revenue for 2025 to be $2,713,476,675, with the lowest ALMS revenue forecast at $2,045,279,792, and the highest ALMS revenue forecast at $3,284,061,243. On average, 10 Wall Street analysts forecast ALMS's revenue for 2026 to be $511,580,109, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $1,159,380,389.
In 2027, ALMS is forecast to generate $1,822,269,992 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $4,371,325,070.